Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21293006 | 1.00 | ALDH1A1 (0.35) | ALDH1A1GAATSHRGLABCHE | |
| SCHEMBL21362361 | 0.82 | ALDH1A1 (0.36) | ALDH1A1GAATSHRBCHEACHE | |
| SCHEMBL20936684 | 0.77 | ALDH1A1 (0.40) | ALDH1A1GAATSHRGLANPC1 | |
| SCHEMBL19872340 | 0.77 | TSHR (0.36) | ALDH1A1GAATSHRMAOB | |
| SCHEMBL15865519 | 0.77 | TSHR (0.36) | ALDH1A1GAATSHRMAOB | |
| SCHEMBL21362364 | 0.76 | BCHE (0.38) | ALDH1A1GAATSHRBCHE | |
| SCHEMBL1250455 | 0.76 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL19856419 | 0.76 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL19856434 | 0.76 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL1666704 | 0.76 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315145-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BICYCLIC UREA COMPOUND | KANEKA CORPORATION (JP) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315145-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BICYCLIC UREA COMPOUND | PGLS, RABGGTA, ALPI | ALDH1A1 2790/4885GAA 6/4885TSHR 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.